Calpain–BDNF/TrkB Disruption After Maternal Surgery

Maternal surgery unrelated to delivery can expose the developing fetus to more than an anesthetic: surgical stress, inflammatory signaling, and changes in maternal physiology may also affect the fetal environment. In their 2025 Neuropharmacology study, Zhang and colleagues investigated whether excessive calpain activity is associated with later cognitive and hippocampal abnormalities in offspring after maternal non-obstetric surgery. The work connects a protease response to BDNF/TrkB signaling and tests whether intervening at either point can improve outcomes.

Study Background and Research Question

BDNF supports neuronal survival and synaptic plasticity in the hippocampus through its receptor TrkB. Changes in this pathway could therefore provide a link between early-life disruption and later learning or memory phenotypes. Calpains are calcium-dependent cysteine proteases that can influence neuronal proteins and cellular structure; excessive activity is a plausible contributor to impaired neuronal integrity. The central question was whether surgery during pregnancy is associated with increased calpain activity and reduced hippocampal BDNF/TrkB signaling in offspring, and whether pharmacological interventions can mitigate the resulting deficits.

A useful feature of the question is its distinction between exposure to propofol and the broader experience of surgery. Prior concerns about anesthetic exposure make propofol a relevant factor, but maternal surgery also entails physiological and stress-related changes. The study’s comparison of surgery-exposed animals with a propofol-alone condition helps address whether anesthetic exposure by itself accounts for the observed outcomes. It does not, however, isolate every component of the surgical response.

Key Innovation from the Reference Study

The study’s main contribution is a linked, intervention-based account of offspring outcomes: maternal surgery was associated with elevated calpain activity, lower BDNF/TrkB-related protein measures, altered neuronal and dendritic features, and impaired behavior. The researchers then tested postnatal treatment with the calpain inhibitor MDL 28170 and, separately, the TrkB agonist 7,8-DHF. Partial improvement after intervention at either point supports the idea that calpain activity and TrkB signaling are functionally relevant to the phenotype.

This is stronger mechanistic evidence than observing a correlation between a protein marker and behavior alone. Yet pharmacological rescue does not by itself show that calpain directly cleaves a particular BDNF/TrkB pathway component, or that this pathway is the only route from maternal surgery to cognitive change. The findings are best read as support for a calpain-associated disruption of trophic signaling and synaptic integrity, with additional work needed to resolve the molecular steps.

Methods and Experimental Design Insights

The investigators used a Sprague-Dawley rat model of maternal non-obstetric surgery during pregnancy and evaluated the offspring. The reported comparisons included a surgery condition and propofol exposure without surgery. Behavioral outcomes included spatial learning and contextual fear memory. Hippocampal assessments covered calpain activity, expression of NeuN and PSD95, BDNF and TrkB measures including phosphorylated TrkB, and dendritic spine density. Postnatal intervention groups received MDL 28170 or the TrkB agonist 7,8-DHF, enabling comparison of intervention at the proposed upstream protease and downstream receptor-signaling levels. The full article is the source for detailed methods and experimental schedules.

Protocol Parameters

• Maternal exposure: The reported model uses pregnant Sprague-Dawley rats undergoing non-obstetric surgery. Consult the full article for operative and anesthetic details rather than inferring them from the abstract.
• Comparator: Propofol alone was included to help distinguish effects associated with surgery from effects of anesthetic exposure alone.
• Offspring outcomes: Behavioral assessment included spatial learning and contextual fear memory, alongside hippocampal molecular and structural measures.
• Postnatal interventions: MDL 28170 and 7,8-DHF were used as separate interventions. Exact doses, treatment timing, and administration details should be taken from the study methods.
• Workflow interpretation: As a research-design suggestion, combine behavioral readouts with target-engagement and structural measures, and include appropriate vehicle and intervention controls. These are general workflow considerations, not additional parameters reported by the study summary.

The combination of behavior, protein measures, and dendritic analysis matters because no single endpoint captures the entire phenotype. For example, a change in PSD95 or spine density can be consistent with altered synaptic organization, but should not be treated as a direct measure of learning. Similarly, these findings do not constitute an apoptosis assay: neuronal integrity markers and cognitive behavior do not, on their own, establish the extent or timing of programmed cell death.

Core Findings and Why They Matter

Offspring in the maternal-surgery condition showed impaired spatial learning and contextual fear memory, whereas propofol alone did not produce the same reported deficits. The surgery-associated phenotype coincided with increased calpain activity and lower hippocampal levels of PSD95, BDNF, TrkB, and phosphorylated TrkB. The study also reported reduced dendritic spine density and decreased NeuN expression, linking the molecular pattern to measures of synaptic structure and neuronal integrity. These results are described in the reference study.

Postnatal treatment with MDL 28170 or 7,8-DHF partially restored protein-expression measures, improved aspects of dendritic and neuronal structure, and improved cognitive performance. The convergence is notable: inhibiting calpain and activating TrkB were each associated with mitigation, consistent with a pathway in which excessive protease activity and weakened trophic signaling contribute to the phenotype. Because rescue was partial, the data also leave room for other consequences of maternal surgery, including effects not corrected by these interventions.

For neuroprotection research, the study offers a framework for testing whether a protease-linked signaling change connects an early exposure to later functional outcomes. Its relevance is not that maternal surgery has been shown to produce the same effects in humans, but that the rat findings identify measurable candidate mechanisms and intervention points for further study. The work also underscores why behavioral and hippocampal endpoints should be interpreted together rather than treating a single molecular change as a proxy for cognition.

Comparison with Existing Internal Articles

The internal overview Calpain, BDNF/TrkB, and Offspring Cognition summarizes the same paper and is useful for a concise account of the proposed pathway and rescue findings. This article adds emphasis on the study’s comparison between surgery and propofol alone, the distinction between observed evidence and mechanistic interpretation, and the limits of pharmacological rescue.

For experimental planning, MDL 28170: A Causal Calpain Assay Strategy frames inhibitor experiments around target engagement, controls, and interpretation. That assay-focused perspective complements the paper: an inhibitor response can support a causal contribution, but it should be paired with measures that test whether the intended target was affected and whether other drug targets could explain part of the result.

Limitations and Transferability

The evidence comes from a rat model, so it does not establish the magnitude, frequency, or mechanism of risk in human pregnancies. Translation requires caution because species, developmental timing, the nature of surgery, and clinical circumstances can differ. The propofol-alone comparator is informative, but it cannot completely separate anesthetic effects from surgical stress, maternal inflammation, endocrine changes, or interactions among these factors.

The interventions also have interpretive limits. MDL 28170 is described in its product information as inhibiting both calpain and cathepsin B. Consequently, improvement after treatment is not, by itself, proof that calpain alone accounts for the rescue. The separate response to a TrkB agonist strengthens the case for BDNF/TrkB involvement, but does not establish that all effects of calpain inhibition pass through that pathway. More selective or orthogonal approaches, alongside direct target-engagement measurements, would help clarify the sequence of molecular events.

Finally, the reported improvements were partial. That pattern is compatible with a contributing pathway rather than a complete explanation of the phenotype. The study supports further investigation of calpain–BDNF/TrkB relationships in developmental neurobiology; it does not establish a preventive or therapeutic strategy for clinical use.

Research Support Resources

Researchers designing related experiments can use MDL 28170, Calpain and Cathepsin B Inhibitor, Selective (SKU A4412) to support similar workflows. Because it also inhibits cathepsin B, experimental interpretation should include suitable controls and, where feasible, independent validation of calpain involvement.